Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA polymerase II-associated protein 3 (RPAP3) is a human protein that acts as a scaffold and co-chaperone within the R2TP complex, interfacing between RNA polymerase II and the HSP90 chaperone system[1][7]. RPAP3’s structure contains tetratricopeptide repeat (TPR) domains and a C-terminal domain that enable it to recruit and stabilize client proteins—including RNA polymerase II—by facilitating their assembly and proper folding through interactions with RUVBL1, RUVBL2, PIH1D1, and HSP90[1][2][4][5]. It is essential for the biogenesis and cellular stability of several large multi-subunit complexes, particularly RNA polymerase II, and may play broader roles in the assembly of protein complexes involved in transcription, cellular stress response, and potentially apoptosis[6][7]. RPAP3 is not, however, an established therapeutic target in current drug discovery or pharmacology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA polymerase II-associated protein 3 (RPAP3).